Immune Checkpoint Therapy in Non-Small Cell Lung Cancer
Kristen A Marrone1, Julie R Brahmer
1From the Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
Abstract:
Lung cancer remains the number one cause of cancer death in the United States. Even with advances in understanding of tumor histology and mutation status, outcomes remain poor with classic cytotoxic therapies. The development of immune checkpoint inhibitors, designed to optimize a host's own immune response against cancer cells, has led to a new era in the treatment of non-small cell lung cancer (NSCLC). Improved survival in trials have led to rapid US Food and Drug Administration approval for these agents in the advanced-stage NSCLC setting. Many studies are looking at these agents across a variety of patient populations, treatment settings, and in combination with other agents. Because of their unique mechanism of action, tumor response kinetics and patient adverse effect profiles vary greatly from cytotoxic chemotherapy and demand further study. Understanding the optimal use of these agents continues to be elucidated as they shift the NSCLC treatment paradigm.
Insights
Immune checkpoint inhibitors represent a new era in treating non-small cell lung cancer (NSCLC), offering improved survival. Further research is needed to fully understand their optimal use and unique patient profiles compared to chemotherapy.
Area of Science:
- Oncology
- Immunology
Background:
- Lung cancer is the leading cause of cancer death in the US.
- Traditional cytotoxic therapies offer limited outcomes for non-small cell lung cancer (NSCLC).
- Advances in understanding tumor biology have paved the way for novel treatments.
Purpose of the Study:
- To review the emergence and impact of immune checkpoint inhibitors in advanced-stage NSCLC.
- To highlight the shift in the NSCLC treatment paradigm driven by these novel immunotherapies.
- To underscore the need for further research into their optimal application and patient-specific effects.
Main Methods:
- Review of clinical trial data and FDA approvals for immune checkpoint inhibitors in NSCLC.
- Analysis of the mechanism of action, response kinetics, and adverse event profiles.
- Exploration of ongoing research in diverse patient populations and combination therapies.
Main Results:
- Immune checkpoint inhibitors have demonstrated improved survival in advanced NSCLC.
- These agents have received rapid FDA approval, signifying a major therapeutic advance.
- Their unique mechanisms lead to different response patterns and side effect profiles compared to chemotherapy.
Conclusions:
- Immune checkpoint inhibitors have revolutionized NSCLC treatment, offering a new therapeutic avenue.
- Optimal utilization and understanding of their distinct characteristics are crucial for maximizing patient benefit.
- Ongoing research continues to refine the role of immunotherapy in the evolving NSCLC landscape.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy